REFERENCES
1. Kamat AM, Hahn NM, Efstathiou JA, Lerner SP, Malmström PU, et al. Bladder cancer. Lancet 2016;388:2796-810.
3. Iacobucci I, Mullighan CG. Genetic basis of acute lymphoblastic leukemia. J Clin Oncol 2017;35:975-83.
4. Litwin MS, Tan HJ. The diagnosis and treatment of prostate cancer: a review. JAMA 2017;317:2532-42.
5. Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature 2018;553:446-54.
6. Lim SH, Johnson PWM. Optimizing therapy in advanced-stage Hodgkin lymphoma. Blood 2018;131:1679-88.
7. Pierorazio PM, Albers P, Black PC, Tandstad T, Heidenreich A, et al. Non-risk-adapted surveillance for stage I testicular cancer: critical review and summary. Eur Urol 2018;73:899-907.
9. Paul CD, Mistriotis P, Konstantopoulos K. Cancer cell motility: lessons from migration in confined spaces. Nat Rev Cancer 2017;17:131-40.
10. Hamidi H, Ivaska J. Every step of the way: integrins in cancer progression and metastasis. Nat Rev Cancer 2018;18:533-48.
11. Sopik V, Rosen B, Giannakeas V, Narod SA. Why have ovarian cancer mortality rates declined? Part III. Prospects for the future. Gynecol Oncol 2015;138:757-61.
12. Erben V, Bhardwaj M, Schrotz-King P, Brenner H. Metabolomics biomarkers for detection of colorectal neoplasms: a systematic review. Cancers (Basel) 2018;10:E246.
13. Li J, Han X, Yu X, Xu Z, Yang G, et al. Clinical applications of liquid biopsy as prognostic and predictive biomarkers in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA. J Exp Clin Cancer Res 2018;37:213.
14. Loke SY, Lee ASG. The future of blood-based biomarkers for the early detection of breast cancer. Eur J Cancer 2018;92:54-68.
15. Sawada T, Hirayama M, Nakata T, Takeda T, Takasugi N, et al. Mass screening for neuroblastoma in infants in Japan. Interim report of a mass screening study group. Lancet 1984;324:271-3.
16. Shinagawa T, Kitamura T, Katanoda K, Matsuda T, Ito Y, et al. The incidence and mortality rates of neuroblastoma cases before and after the cessation of the mass screening program in Japan: a descriptive study. Int J Cancer 2017;140:618-25.
17. Gøtzsche PC, Jørgensen KJ. Screening for breast cancer with mammography. Cochrane Database Syst Rev 2013:CD001877.
18. Bleyer A. Screening mammography: update and review of publications since our report in the New England Journal of Medicine on the magnitude of the problem in the United States. Acad Radiol 2015;22:949-60.
19. Ripping TM, Ten Haaf K, Verbeek ALM, van Ravesteyn NT, Broeders MJM. Quantifying overdiagnosis in cancer screening: a systematic review to evaluate the methodology. J Natl Cancer Inst 2017;109:doi: 10.1093/jnci/djx060.
20. Wallis MG. How do we manage overdiagnosis/overtreatment in breast screening? Clin Radiol 2018;73:372-80.
22. Zaffiri L, Gardner J, Toledo-Pereyra LH. History of antibiotics. From salvarsan to cephalosporins. J Invest Surg 2012;25:67-77.
23. Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 2013;13:714-26.
24. Zaffiri L, Gardner J, Toledo-Pereyra LH. History of antibiotics: from fluoroquinolones to daptomycin (Part 2). J Invest Surg 2013;26:167-79.
25. De Clercq E, Li G. Approved antiviral drugs over the past 50 years. Clin Microbiol Rev 2016;29:695-747.
26. Sachs JR, Mayawala K, Gadamsetty S, Kang SP, de Alwis DP. Optimal dosing for targeted therapies in oncology: drug development cases leading by example. Clin Cancer Res 2016;22:1318-24.
27. Wong KM, Capasso A, Eckhardt SG. The changing landscape of phase I trials in oncology. Nat Rev Clin Oncol 2016;13:106-17.
28. McCarthy MW, Kontoyiannis DP, Cornely OA, Perfect JR, Walsh TJ. Novel agents and drug targets to meet the challenges of resistant fungi. J Infect Dis 2017;216:S474-83.
29. Gatzka MV. Targeted tumor therapy remixed-an update on the use of small-molecule drugs in combination therapies. Cancers (Basel) 2018;10:E155.
30. Kavanagh S, Nee A, Lipton JH. Emerging alternatives to tyrosine kinase inhibitors for treating chronic myeloid leukemia. Expert Opin Emerg Drugs 2018;23:51-62.
31. Kleczko EK, Heasley LE. Mechanisms of rapid cancer cell reprogramming initiated by targeted receptor tyrosine kinase inhibitors and inherent therapeutic vulnerabilities. Mol Cancer 2018;17:60.
32. Larionov AA. Current therapies for human epidermal growth factor receptor 2-positive metastatic breast cancer patients. Front Oncol 2018;8:89.
33. Sharma GG, Mota I, Mologni L, Patrucco E, Gambacorti-Passerini C, et al. Tumor resistance against ALK targeted therapy-where it comes from and where it goes. Cancers (Basel) 2018;10:E62.
34. Soverini S, Mancini M, Bavaro L, Cavo M, Martinelli G. Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy. Mol Cancer 2018;17:49.
35. Tomasello C, Baldessari C, Napolitano M, Orsi G, Grizzi G, et al. Resistance to EGFR inhibitors in non-small cell lung cancer: clinical management and future perspectives. Crit Rev Oncol Hematol 2018;123:149-61.
36. Bock C, Lengauer T. Managing drug resistance in cancer: lessons from HIV therapy. Nat Rev Cancer 2012;12:494-501.
37. Garbelli A, Riva V, Crespan E, Maga G. How to win the HIV-1 drug resistance hurdle race: running faster or jumping higher? Biochem J 2017;474:1559-77.
38. Britt WJ, Prichard MN. New therapies for human cytomegalovirus infections. Antiviral Res 2018;159:153-74.
39. Hamers RL, Rinke de Wit TF, Holmes CB. HIV drug resistance in low-income and middle-income countries. Lancet HIV 2018;5:e588-96.
40. Anderson R, Rapoport BL. Immune dysregulation in cancer patients undergoing immune checkpoint inhibitor treatment and potential predictive strategies for future clinical practice. Front Oncol 2018;8:80.
41. Davis MP, Panikkar R. Checkpoint inhibitors, palliative care, or hospice. Curr Oncol Rep 2018;20:2.
